The effect of CYP3A5 and ABCBl single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients

Annals of Transplantation

Volumn 14, Issue 1, 2009, Pages 23-31

  Provenzani, Alessio ^a   Notarbartolo, Monica ^b   Labbozzetta, Manuela ^b   Poma, Paola ^b   Biondi, Filippo ^b   Sanguedolce, Rosario ^b   Vizzini, Giovanni ^a   Palazzo, Ugo ^a   Polidori, Piera ^a   Triolo, Fabio ^a   Gridelli, Bruno ^a   D'Alessandro, Natale ^b  

^a MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

ABCB1; CYP3A5; Liver transplant; Single nucleotide polymorphisms; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; LIVER TRANSPLANTATION; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CAUCASIAN; GENETICS; HOMOZYGOTE; IMMUNOLOGY;

CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 67549139183     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Venkataraman R, Swaminatan A, Prasad T et al: Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet, 1995; 29: 404-30
2. Ihara H, Shinkuma D, Ichikawa Y et al: Intra-and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Urol, 1995; 2:151-55
3. Jusko WJ: Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit, 1995; 17: 596-601
4. Lampen A, Christians U, Guengerich FP et al: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos, 1995; 23: 1315-24
5. Staatz CE, Willis C, Taylor PJ et al: Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transp, 2003; 9:130-37
6. Kalow W, Tang BK, Endrenyi L: Hypothesis. Comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics, 1998; 8: 283-89
7. Sattler M, Guengerich FP, Yun CH et al: Cytochrome P-450 3A enzymes are responsible for biotransfor-mation of FK506 and rapamycin in man and rat. Drug Metab Dispos, 1992; 20: 753-61
8. Thummel KE, Wilkinson GR In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998; 38: 389-430
9. Cholerton S, Daly AK, Idle JR The role of individual human cytochrome P450 in drug metabolism and clinical response. Trends Pharmacol Sci, 1992; 13: 434-39
10. Kuehl P, Zhang J, Lin Y et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001; 27: 383-91
11. Goto M, Masuda S, Kiuchi T et al: CYP3A5*l-car-rying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics, 2004; 14: 471-78
12. Macphee I, Fredericks S, Tai T et al: Tacrolimus pharmacogenetics. Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 2002; 74:1486-89
13. Zheng H, Zeevi A, Schuetz E et al: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol, 2004; 44: 135-40
14. Tsuchiya N, Satoh S, Tada H et al: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 2004; 78:1182-87
15. Saeki T, Ueda K, Tanigawara Y et al: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem, 1993; 268: 6077-80
16. Thiebaut F, Tsuruo T, Hamada H et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue. Proc Natl Acad Sci USA, 1987; 84: 7735-38
17. Hall SD, Thumel KE, Watkins PB et al: Molecular and physical mechanisms of first-pass extraction. Drug Metabol Dispos, 1999; 27:161-66
18. Zhang Y, Benet LZ: The gut as a barrier to drug absorption. Combined role of cytochrome P450 3Aand P-glycoprotein. Clin Pharmacokinet, 2001; 40:159-68
19. Hoffmeyer S, Burk O, von Richter O et al: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000; 97: 3473-78
20. Siegmund W, Ludwig K, Giessmann T et al: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther, 2002; 72: 572-83
21. Anglicheau D, Verstuyft C, Laurent-Puig P et al: Association of the multidrug resistance-1 gene sin-gle-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol, 2003; 14:1889-96
22. Wang D, Johnson AD, Papp AC et al: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics, 2005; 15: 693-704
23. Fredericks S, Moreton M, Reboux S et al: Multi-drug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705-8
24. Li D, Gui R, Huanz Z, Nie X: Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc, 2006; 38: 2580-82
25. von Ahsen N, Richter M, Grupp C et al: No influence of the MDR-1 C3435T polymorphisms or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentration or rejection incidence in stable renal transplant recipients. Clin Chem, 2001; 47: 1048-52
26. Min DI, Ellingrod VL: C3435T mutation in exon 26 of the human MDR-1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit, 2002; 24: 400-4
27. Jeannesson E, Albertini L, Siest G et al: Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol, 2007; 21: 411-18
28. Cascorbi I, GerioffT, Johne A et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharm Ther, 2001; 69: 169-74
29. Utecht KN, Hiles JJ, Kolesar J: Effects of genetic polymorphisms on the pharmacokinetics of cal-cineurin inhibitors. Am J Health Syst Pharm, 2006; 63: 2340-48
30. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther, 1994; 270: 414-23
31. Schmucker DL, Woodhouse KW, Wang RK et al: Effects of age and gender on in vitro propertiesof human liver microsomal monoxygenases. ClinPharmacol Ther, 1990: 48; 365-74
32. George J, Byth K, Farrell GC: Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol, 1995; 50: 727-30
33. Lee JY, Hahn HJ, Son IJ et al: Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy, 2006; 26:1069-77
34. Cotreau MM, Von Moltke LL and Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P4503A substrates. Clin Pharmacokinet, 2005; 44: 33-60
35. Mourad M, Mourad G, Wallemacq P et al: Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation, 2005; 80:977-84
36. Anglicheau D, Flamant M, Schlageter MH et al: Pharmacokinetic interaction between corticoster-oids and tacrolimus after renal transplantation. Nephrol Dial Transplant, 2003; 18: 2409-14
37. Shimada T, Terada A, Yokogawa K et al: Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation, 2002; 74: 1419-24
38. Lamba JK, Lin YS, Shuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev, 2002; 54:1271-94
39. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem, 2002; 48: 1668-71
40. Hustert E, Haberl M, Burk O et al: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 2001; 11: 773-79
41. Dirks NL, Huth B, Yates CR, Meibohm B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. IntJ Clin Pharmacol Ther, 2004; 42: 701-18
42. Ifergan I, Bernard NF, Bruneau J et al: Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HlV-nega-tive and HIV-positive Caucasians. AIDS, 2002; 16: 2340-42
43. Cavaco I, Gil JP, Gil-Berglund E and Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab, 2003; 41:1345-50
44. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among Europeans Americans and African Americans. Clin Pharmacol Ther, 2001; 70:189-99
45. Ameyaw MM, Regateiro F, Li T et al: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 2001; 11: 217-21.
46. Wang J, Zeevi A, McCurry K et al: Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing adult lung transplant patients who are CYP3A5*3/*3 non-expressors. Transplant Immunology, 2006; 15: 235-40
47. Dai Y, Hebert MF, Isoherranen N et al: Effects of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos, 2007; 34: 836-47
48. Li D, Lu W, ZhuJY et al: Population pharmacoki-netics of tacrolimus and CYP3A5, MDR-1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther, 2007; 32: 505-15
49. Thervet E, Anglicheau D, King B et al: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to dose ratio in renal transplant recipients. Transplantation, 2003; 76: 1233-35
50. Zheng H, Webber S, Zeevi A et al: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant, 2003; 3: 477-83
51. MacPhee LA, Fredericks S, Tai T et al: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant, 2004; 4: 914-19
52. Yu S, Wu L, JinJ et al: Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation, 2006; 81: 46-51
53. Uesugi M, Masuda S, Katsura T et al: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics, 2006; 16:119-27
54. Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodinamics of drugs. Pharmacogenomics, 2003; 4: 397-410
55. Haufroid V, Mourad M, Van Kerckhove V et al: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 2004; 14:147-54
56. 0 or C, measurements. Clin Transplant, 2007; 21: 252-57
57. Mai I, Perloff ES, Bauer S et al: MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol, 2004; 58: 548-53
58. Op den Buijsch RA, Christiaans MH, Stolk LM et al: Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-bind-ing cassette Bl (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol, 2007; 21: 427-35
59. Tada H, Tsuchiya N, Satoh H: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc, 2005; 37: 1730-32
60. Zahir H, McLachlan AJ, Nelson A et al: Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit, 2005; 27: 422-30
61. Christians U, Strom T, Zhang YL et al: Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodinamics. Ther Drug Monit, 2006; 28: 39-44
62. Burckart GJ and Liu XI. Pharmacogenetics in transplant patients. Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit, 2006; 28: 23-30